Study Keyword: Programmed Cell Death 1 Ligand 2

A Study of Co-formulated Favezelimab/Pembrolizumab Versus Doctor’s Choice Chemotherapy in PD-1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma

By

The purpose of this study is to compare efficacy of co-formulated favezelimab/pembrolizumab (MK-4280A) with doctor’s choice chemotherapy of bendamustine or gemcitabine in participants with PD-(L)1-refractory, relapsed or refractory classical Hodgkin Lymphoma. The study will also assess the safety and tolerability of co-formulated favezelimab/pembrolizumab. The primary study hypotheses are that co-formulated favezelimab/pembrolizumab is superior to doctor’s … Continued

A Study of Belzutifan Plus Pembrolizumab Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post-Nephrectomy

By

The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post-nephrectomy. The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect … Continued

Study of Pembrolizumab Versus Chemotherapy in Mismatch Repair Deficient Advanced or Recurrent Endometrial Carcinoma

By

The purpose of this study is to assess the safety and efficacy of treatment with pembrolizumab (MK-3475) compared to a combination of carboplatin and paclitaxel in women with mismatch repair deficient (dMMR) advanced or recurrent endometrial carcinoma who have not previously been treated with prior systemic chemotherapy. The primary study hypotheses are that pembrolizumab is … Continued